Overview
Neuralstem develops neural stem cell-based therapies and small-molecule compounds targeting neurological conditions including ALS and spinal cord injury.
More in Neuropharmaceuticals
Latest industry news
University of Michigan Completes First Long-Term Wireless Brain-Computer Interface Implant in Humans
2026-07-07 · Research
Synchron Closes $275M Series E to Accelerate Stentrode BCI Commercialization
2026-06-29 · Funding
Precision Neuroscience Closes $120M Series D to Accelerate Cortical Array Commercialization
2026-06-24 · Funding
It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
2026-06-23 · Product
Company details
Category
💊 Neuropharmaceuticals
Location
Germantown, MD, USA
Funding
Publicly traded (NASDAQ: CUR)
Website
www.neuralstem.comListed
2026-07-06
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →